期刊文献+

屏障法和药物干预男性避孕的研究进展 被引量:1

Research advances of barrier methods and pharmaceutical intervention methods in male contraception
原文传递
导出
摘要 男性避孕可分为屏障法、药物干预法和其他三类。屏障法包括避孕套、输精管结扎术、可逆性抑精剂(RISUG)、Vasalgel等,药物干预分为激素类和非激素类。激素类男性避孕药基于下丘脑-垂体-性腺轴的负反馈调节影响精子发生达到避孕目的。大多数非激素类避孕药因其具有特异性高、毒副作用低和可逆性恢复等优点而成为开发热点。其他有应用射线、微波、纳米物质、高温封闭等研究开发避孕的方法。本文主要对屏障法和药物干预法进行系统综述。 Male contraceptive methods can be divided into barrier methods, pharmaceutical intervention methods and the other. Barrier methods include condoms, vasoligation, reversible inhibition sperm under guidance(RISUG) and Vasalgel, etc. Pharmaceutical intervention methods can be further classified as hormonal and non-hormonal male contraceptive. Hormone-based male contraceptives based on negative feedback regulation of the hypothalamic-pituitary-gonadal axis affect spermatogenesis for contraceptive purposes. Development of non-hormonal male contraceptive is a trend because of the advantages of high specificity, hypotoxicity and reversibility. In addition, there are some contraceptive researches by the use of radiation, microwaves, nanomaterials, and high-temperature sealing. Herein we focus on a systematic review of barrier methods and pharmaceutical intervention methods.
作者 陈志婷 于合国 杨依婷 施惠娟 谢淑武 刁华 Chen Zhiting;Yu Heguo;Yang Yiting;Shi Huijuan;Xie Shuwu;Diao Hua(Fudan University Shanghai Medical College,Shanghai 200032,China;Key Labatory of Reproduction Regulation ofNPFPC,SIPPR,IRD,Fudan University,Shanghai 200032,China)
出处 《中华生殖与避孕杂志》 CAS CSCD 北大核心 2018年第5期432-437,共6页 Chinese Journal of Reproduction and Contraception
基金 国家重点研发计划(2016YFC1000905) 上海市科技支撑项目(15431903000) 国家自然科学基金面上项目(81671508)
关键词 避孕方法 屏障法 激素类避孕药 非激素避孕药 靶点 Contraceptive method Barriers methods Hormonal contraceptive Nonhormonal contraceptive Target
  • 相关文献

参考文献3

二级参考文献23

  • 1李明华,郭小斌,方瑞英,章元沛.十一酸睾丸素的药理作用与临床应用[J].新药与临床,1994,13(5):279-281. 被引量:3
  • 2Contraceptive efficacy of testosterone-induced azoospermia in normal men.World Health Organization Task Force on methods for the regulation of male fertility[J].Lancet,1990,336(8721):955-959.
  • 3Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men[J].Fertil Steril,1996,65(4):821-829.
  • 4Nieschlag E.Sixth Summit Meeting on Male Contraception Consensus:recommendations for regulatory approval for male hormonal contraception[J].Int J Androl,2002,25(6):375.
  • 5World Health Organization.WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction[M].4th ed.Cambridge,UK:Cambridge University Press,1999:4-22.
  • 6Turner L,Conway AJ,Jimenez M,et al.Contraceptive efficacy of a depot progestin and androgen combination in men[J].J Clin Endocrinol Metab,2003,88(10):4659-4667.
  • 7Trussell J.Contraceptive failure in the United States[J].Contraception,2004,70(2):89-96.
  • 8KostK,Singh S,Vaughan B,et al.Estimates of contraceptive failure from the 2002 National Survey of Family Growth[J].Contraception,2008,77(1):10-21.
  • 9Wang C.Clinical studies using androgen alone for male contraceptive development[A].In:Rajalakshmi M,Griffin PD,eds.Male contraception:present and future[M].New Delhi,India:New Age International Publishers,1999:189-200.
  • 10Ly LP,Liu PY,Handelsman DJ.Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens[J].Hum Reprod,2005,20(6):1733-1740.

共引文献4

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部